Related Experiment Videos
Clinical applications of vascular gene therapy
J Rutanen1, T T Rissanen, A Kivelä
1A.I. Virtanen Institute, University of Kuopio and Kuopio University Hospital, PO Box 1627, FIN-70211, Kuopio, Finland.
Insights
Vascular gene therapy shows promise for treating coronary artery disease by promoting collateral vessel growth. Further research is needed to optimize gene transfer vectors and delivery for improved safety and efficacy in humans.
Area of Science:
- Cardiovascular Medicine
- Molecular Biology
- Gene Therapy
Background:
- Coronary artery disease (CAD) is a leading cause of death globally, with current treatments like bypass surgery and angioplasty facing limitations such as restenosis and graft occlusion.
- The body naturally forms collateral vessels to bypass blockages, but these are often insufficient to restore adequate blood flow (ischemia).
Purpose of the Study:
- To explore vascular gene transfer as a novel therapeutic strategy for CAD.
- To highlight the potential of gene therapy in overcoming limitations of current interventional procedures.
Main Methods:
- Review of existing research on vascular gene transfer for cardiovascular applications.
- Analysis of preclinical (animal models) and early clinical trial data.
Main Results:
- Gene transfer using vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and E2F decoy has demonstrated potential in animal models and initial human trials.
- These approaches aim to enhance collateral circulation to improve blood supply.
Conclusions:
- Vascular gene therapy presents a promising avenue for treating ischemic cardiovascular diseases.
- Further research is essential to refine gene transfer vectors, delivery methods, and identify optimal therapeutic genes to enhance the efficacy and safety of human vascular gene therapy.
Abstract:
Despite significant advances in prevention, coronary artery disease remains the leading cause of death in the Western world. Surgical bypass and angioplasty are the primary interventional therapies but they are limited by the problems of restenosis and graft occlusions. Natural response to vascular occlusion involves the formation of collateral vessels that bypass obstructions, but they are often inefficient in relieving ischemia. Vascular gene transfer offers a promising new approach to solve these problems. Its potential has been shown in animal models and in first human trials using vascular endothelial growth factor, fibroblast growth factor, and E2F cell-cycle transcription factor decoy. However, further basic research on gene transfer vectors, gene delivery techniques, and identification of effective treatment genes is needed to improve the efficacy and safety of human vascular gene therapy.